NeoGenomics rises 4% premarket on BTIG upgrade to 'buy'
NeoGenomics shares jumped more than 4% to $19.92 in premarket trading after BTIG upgraded its rating to 'buy' from 'neutral', citing Medicare coverage for its RaDaR ST test and potential growth from the PanTracer LBx blood test. BTIG set its price target at $28.